Professional Experience
Christopher E. Loh practices general intellectual property law with an emphasis on biotechnology and Hatch-Waxman pharmaceutical patent litigation. Mr. Loh has litigated patent cases involving such diverse technologies as anticonvulsants, antisense probes, cholesterol-lowering statins, calcium-channel blockers and vascular stents. Mr. Loh also has significant experience in drafting licensing agreements, preparing noninfringement and freedom-to-operate opinions, and advising clients on complex intellectual property transactions.
Mr. Loh has twice won the Burton Award For Legal Achievement, which acknowledges exceptional examples of legal writing, for his articles "Patent Exhaustion Revitalized?" in the August 18, 2008 issue of the New York Law Journal, and "How To Assess Trade Secret Damages" from the June 2006 issue of Managing Intellectual Property. Mr. Loh also has written for the National Law Journal,
Bloomberg IP and Lexology.
Mr. Loh received his law degree from Columbia University and dual undergraduate degrees in Molecular Biochemistry & Biophysics and Economics from Yale University. While in law school, Mr. Loh served as Notes Editor for the Columbia Business Law Review and interned at the New York Volunteer Lawyers for the Arts, counseling clients on copyright, trademark and artist rights issues.
Professional Activities
American Bar Association; New York State Bar Association; New York Intellectual Property Law Association
Additional Publications
"Developments in European Patent Law", New York Law Journal Intellectual Property Law Special Section, May 7, 2001
"Congress Takes Aim At Business Method Patents", New York Law Journal, March 6, 2001
Decisions
Representative Cases
Genzyme Corporation v. Pentech Pharmaceuticals, Inc. and Cobrek, Inc.
N.D. Ill. 2012
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. and Mylan Inc.
D.N.J. 2011
AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd., v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd and Sandoz, Inc.
Fed. Cir. 2009
AstraZeneca Pharmaceutical LP et al. v. Teva Pharmaceuticals USA, Inc, et al.
D.N.J. 2008
AstraZeneca Pharmaceuticals LP, et al. v. Teva Pharmaceuticals USA, Inc., et al.
D.N.J. 2007
Adams Respiratory Operations, Inc. v. Mutual Pharmaceutical Co., et al.
E.D.Pa. 2007
Sky Technologies LLC v IBM Corporation
E.D. Tx. 2006
SmithKline Beecham Corporation v. Teva Pharmaceuticals USA, Inc.
D.N.J. 2004
AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc.
E.D.Pa. 2002
Allergan v. Bausch & Lomb and Alcon
C.D. Cal., 2002
Publications
Caraco Holds That Statutory Counterclaim To Correct Patent Information Submitted By Branded Drug Makers To FDA Applies To Inaccurate Use Codes For Method-Of-Use Patents
Fitzpatrick Case Update
April 18, 2012
A Myriad of Amicus Briefs
Executive Counsel
Major DNA Patent Case Before The Federal Circuit
February/March 2011
Variations on a Theme: Five Approved Abbreviated Approval Pathways for Biologics
Bloomberg Health Law
April 2009
Law of patent anticipation gets a new twist
The National Law Journal
January 19, 2009
What KSR did and did not change about the law of patent obviousness
Benchmark Litigation: The Definitive Guide to America's Leading Litigation Firms & Attorneys
October 2008
Patent exhaustion revitalized?
The National Law Journal
August 18, 2008
How To Assess Trade Secret Damages
Managing Intellectual Property
June 2006